Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu's arteritis

被引:15
作者
Koga, Tomohiro [2 ,3 ]
Nishino, Yuichiro [2 ,3 ]
Makiyama, Junya [2 ]
Hayashida, Takeshi [4 ]
Miyashita, Taichiro [2 ,3 ]
Izumi, Yasumori [2 ,3 ]
Tamai, Mami [5 ]
Kawakami, Atsushi [5 ]
Eguchi, Katsumi [5 ]
Migita, Kiysohi [1 ,3 ]
机构
[1] NHO Natl Nagasaki Med Ctr, Clin Res Ctr, Nagasaki 8568562, Japan
[2] NHO Natl Nagasaki Med Ctr, Dept Gen Internal Med, Nagasaki 8568562, Japan
[3] NHO Natl Nagasaki Med Ctr, Dept Rheumatol, Nagasaki 8568562, Japan
[4] Nagasaki Univ, Sch Med, Dept Radiol, Nagasaki 8528501, Japan
[5] Nagasaki Univ, Sch Med, Dept Rheumatol, Nagasaki 8528501, Japan
关键词
C-reactive protein; F-18]-FDG-PET; Serum amyloid A; Takayasu's arteritis; MECHANISMS; VESSEL;
D O I
10.1007/s00296-009-1296-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Takayasu's arteritis (TA) is a rare large vessel vasculitis that is difficult to diagnose in the early stages. Therefore, it is also very difficult to manage and prevent irreversible vascular damage in TA. A 19-year-old female patient with back pain was examined using [F-18]-FDG-PET to detect the source of inflammation. Specific accumulation of [F-18]-FDG was observed in the thoracic and abdominal aorta, leading to the diagnosis of TA. Corticosteroid treatment resulted in clinical remission. However, the serum amyloid A (SAA) levels remained elevated. A follow-up scan showed residual uptake of [F-18]-FDG in the thoracic aorta suggesting subclinical vascular inflammation. Methotrexate was combined with the corticosteroid, and the elevated levels of SAA became normalized. The present case suggests that monitoring serum levels of SAA and [F-18]-FDG-PET could help clinicians to make adequate treatment adjustments in TA patients.
引用
收藏
页码:561 / 563
页数:3
相关论文
共 11 条
  • [1] Takayasu's arteritis - recent advances in imaging offer promise
    Andrews, J.
    Mason, J. C.
    [J]. RHEUMATOLOGY, 2007, 46 (01) : 6 - 15
  • [2] Treatment and outcomes of large vessel arteritis
    Borg, Frances A.
    Dasgupta, Bhaskar
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2009, 23 (03): : 325 - 337
  • [3] Cunnane G, 2000, J RHEUMATOL, V27, P58
  • [4] Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation
    Gabay, C
    Kushner, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) : 448 - 454
  • [5] TAKAYASU ARTERITIS
    KERR, GS
    HALLAHAN, CW
    GIORDANO, J
    LEAVITT, RY
    FAUCI, AS
    ROTTEM, M
    HOFFMAN, GS
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 120 (11) : 919 - 929
  • [6] Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice
    Malle, E
    deBeer, FC
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (06) : 427 - 435
  • [7] Overview of Late Outcome of Medical and Surgical Treatment for Takayasu Arteritis
    Ogino, Hitoshi
    Matsuda, Hitoshi
    Minatoya, Kenji
    Sasaki, Hiroaki
    Tanaka, Hiroshi
    Matsumura, Yu
    Ishibashi-Ueda, Hatsue
    Kobayashi, Junjiro
    Yagihara, Toshikatsu
    Kitamura, Soichiro
    [J]. CIRCULATION, 2008, 118 (25) : 2738 - 2747
  • [8] Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis
    Park, MC
    Lee, SW
    Park, YB
    Lee, SK
    [J]. RHEUMATOLOGY, 2006, 45 (05) : 545 - 548
  • [9] Salvarani C, 2003, CLIN EXP RHEUMATOL, V21, pS23
  • [10] Takayasu's arteritis: A study of 104 Italian patients
    Vanoli, M
    Daina, E
    Salvarani, C
    Sabbadini, MG
    Rossi, C
    Bacchiani, G
    Schieppati, A
    Baldissera, E
    Bertolini, G
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (01): : 100 - 107